Evidence map›Paper›PMID 36119114›Full record

ArticleFrontiers in immunology2022

Lyl1-deficiency promotes inflammatory responses and increases mycobacterial burden in response to

Shelby-Sara Jones, Mumin Ozturk, Nathan Scott Kieswetter, Sibongiseni K L Poswayo, Rudranil Hazra, Ousman Tamgue, Suraj P Parihar, Harukazu Suzuki, Frank Brombacher, Reto Guler

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in immunology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact, top 89% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 4 institutions in 4 countries.

Shelby-Sara JonesInternational Centre for Genetic Engineering and Biotechnology, Cape Town Component, Cape Town, South Africa.
Mumin OzturkInternational Centre for Genetic Engineering and Biotechnology, Cape Town Component, Cape Town, South Africa.
Nathan Scott KieswetterInternational Centre for Genetic Engineering and Biotechnology, Cape Town Component, Cape Town, South Africa.
Sibongiseni K L PoswayoInternational Centre for Genetic Engineering and Biotechnology, Cape Town Component, Cape Town, South Africa.
Rudranil HazraWellcome Centre for Infectious Diseases Research in Africa (CIDRI-Africa), Institute of Infectious Disease and Molecular Medicine (IDM), Faculty of Health Sciences, University of Cape Town, Cape Town, South Africa.
Ousman TamgueInternational Centre for Genetic Engineering and Biotechnology, Cape Town Component, Cape Town, South Africa.
Suraj P PariharWellcome Centre for Infectious Diseases Research in Africa (CIDRI-Africa), Institute of Infectious Disease and Molecular Medicine (IDM), Faculty of Health Sciences, University of Cape Town, Cape Town, South Africa.
Harukazu SuzukiLaboratory for. Cellular Function Conversion Technology RIKEN Center for Integrative Medical Sciences, Yokohama, Japan.
Frank BrombacherInternational Centre for Genetic Engineering and Biotechnology, Cape Town Component, Cape Town, South Africa.
Reto GulerInternational Centre for Genetic Engineering and Biotechnology, Cape Town Component, Cape Town, South Africa.
University of Cape Town · ZASouth African Medical Research Council · ZAInternational Centre for Genetic Engineering and Biotechnology · ZARIKEN Center for Integrative Medical Sciences · JP

Funding

Medical Research Council MR/P028071/1Wellcome Trust
6 · The paper itself

Abstract

Lymphoblastic leukemia 1 (Lyl1) is a well-studied transcription factor known to exhibit oncogenic potential in various forms of leukemia with pivotal roles in hematopoietic stem cell biology. While its role in early hematopoiesis is well established, its function in mature innate cells is less explored. Here, we identified Lyl1 as a drastically perturbed gene in the

Indexed as

Precursor Cell Lymphoblastic Leukemia-LymphomaTuberculosisAnimalsBasic Helix-Loop-Helix ProteinsInterleukin-1MiceNeoplasm ProteinsNF-kappa BNitric OxideBasic Helix-Loop-Helix ProteinsInterleukin-1Lyl1 protein, mouseNeoplasm ProteinsNF-kappa BNitric Oxideinnate immunitylymphoblastic leukemia 1Mycobacterium tuberculosisneutrophilic inflammationtranscription factor

Identifiers

PMID36119114
PMCPMC9481033
OpenAlexW4294168343

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.